Metformin
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Syndrome X
Conditions
Metabolic Syndrome X, Diastolic Dysfunction, Insulin Resistance
Trial Timeline
Jan 1, 2014 → Dec 1, 2019
NCT ID
NCT02017561About Metformin
Metformin is a phase 2 stage product being developed by Merck for Metabolic Syndrome X. The current trial status is completed. This product is registered under clinical trial identifier NCT02017561. Target conditions include Metabolic Syndrome X, Diastolic Dysfunction, Insulin Resistance.
What happened to similar drugs?
19 of 20 similar drugs in Metabolic Syndrome X were approved
Approved (19) Terminated (4) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04500678 | Phase 2/3 | UNKNOWN |
| NCT02017561 | Phase 2 | Completed |
| NCT02710448 | Phase 2 | Completed |
| NCT00390273 | Phase 1/2 | Completed |
| NCT00134303 | Approved | Completed |
| NCT00303537 | Phase 2/3 | UNKNOWN |
Competing Products
20 competing products in Metabolic Syndrome X